A new paper related to the MVVC project has recently been published in the PLoS One journal.
The article “Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal” was published by Victorine Mensah et al. in PLoS One. It shows that this pre-erythrocytic malaria vaccine is safe and induces significant immunogenicity with a peak T-cell response at seven days after boosting of 932 Spot Forming Cells (SFC)/106 Peripheral Blood Mononuclear Cells (PBMC) compared to 57 SFC/ 106 PBMCs in the control group. Furthermore, the article confirms that vaccine efficacy against malaria infection in adults may be rapidly assessed using this efficient and cost-effective clinical trial design. EVI congratulates Victorine Mensah and the co-authors for this intersting information.